Opinions

Novel strategies are offering the possibility of extended patient survival and durable disease control

Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes 

While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice

Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge

Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain

Although genomics-guided personalised cancer vaccines have demonstrated efficacy in early-phase clinical studies, we are still awaiting the results of larger-scale trials

Interest is growing rapidly in the field of oncology in the anti-obesity drug target that has recently been investigated in large retrospective studies and preclinical models

Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity

Early studies investigated the potential of genomic profiling, but prospective and comprehensive data are required to support wider implementation

Study results support alternative treatment regimens in prostate and urothelial tumours, showing similar efficacy to standard care while reducing treatment burden